Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders;Klinik, diagnostik und therapie HIV-induzierter neuropsychiatrischer störungen

Wiener Medizinische Wochenschrift

Volumn 156, Issue 23-24, 2006, Pages 644-656

  Rothenhäusler, Hans Bernd ^a,b  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Diagnosis; Highly active antiretroviral therapy; HIV infection; HIV induced neuropsychiatric disorders; Therapy

Indexed keywords

ABACAVIR; ACICLOVIR; ALPHA INTERFERON; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHLORAMPHENICOL; CIPROFLOXACIN; CLOZAPINE; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSCARNET; GANCICLOVIR; INDINAVIR; ISONIAZID; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OFLOXACIN; PENICILLIN G; PYRIMETHAMINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG PROTEIN BINDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENTAL DISEASE; MOOD DISORDER; NEUROPSYCHIATRY; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; COGNITION DISORDERS; COHORT STUDIES; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MENTAL DISORDERS; MOOD DISORDERS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 33846197479     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-006-0353-y     Document Type: Review

References (95)

1. Cohen J (2002) AIDS research. Longtime rivalry ends in collaboration. Science 295: 1441-1442
2. Nakasujja N, Musisi S, Robertson K, Wong M, Sacktor N, Ronald A (2005) Human immunodeficiency virus neurological complications: an overview of the Ugandan experience. J Neurovirol 11(Suppl3): 26-29
3. Bartlett JG (1993) Human immunodeficiency virus infection. New Horiz 1: 302-311
4. Rao YG, Mirza DF (2005) Infections transmitted from donors to recipients following organ transplantation. Natl Med J India 18: 189-194
5. Fischl MA, Parker CB, Pettinelli C, Wulfsohn M, Hirsch MS, Collier AC, Antoniskis D, Ho M, Richman DD, Fuchs E (1990) A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clincial Trials Group. N Engl J Med 323: 1009-1014
6. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333: 450-451
7. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonhard J (1998) Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351: 543-549
8. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Philipps AN, Lundgren JD, EuroSIDA study group (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29
9. Manzardo C, Del Mar Ortega M, Sued O, Garcia F, Moreno A, Miro JM (2005) Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol 11(Suppl3): 72-82
10. Cinque P, Robertson K, Antinori A, Price RW (2005) Neurological complications of HIV infection and AIDS: current and future perspectives. J Neurovirol 11(Suppl3): 1-5
11. Koutsilieri E, Scheller C, Sopper S, ter Meulen V, Riederer P (2002) Psychiatric complications in human immunodeficiency virus infection. J Neurovirol 8(Suppl2): 129-133
12. Dolder CR, Patterson TL, Jeste DV (2004) HIV, psychosis and aging: past, present and future. AIDS 18(Suppl1): 35-42
13. Von Einsiedel RW, Berger T, Weisbrod M, Unverricht S, Hartmann M (2001) HIV-Patienten mit psychiatrischen Krankheiten. Nervenarzt 72: 204-215
14. Ferrando SJ, Wapenyi (2002) Psychopharmacological treatment of patients with HIV and AIDS. Psychiatr Q 73: 33-48
15. Treisman GJ, Kaplin AI (2002) Neurologic and psychiatric complications of antiretroviral agents. AIDS 16: 1201-1215
16. Centers for Disease Control and Prevention (CDC) (1992) 1993 Revision classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 41 (no. RR-17)
17. Pantaleo G, Graziosi C, Fauci AS (1993) The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328: 327-335
18. Brockmeyer NH (2003) Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. Dtsch Med Wochen sehr 128: 7-18
19. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC. Cleary P (1988) The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239: 586-592
20. Ellen SR, Judd FK, Mijch AM, Cockram A (1999) Secondary mania in patients with HIV infection. Aust NZJ Psychiatry 33: 353-360
21. Ciesla J, Roberts J (2001) Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 158: 725-730
22. Sewell DD, Jeste DV, Atkinson JH, Heaton RK, Hesselink JR, Wiley C, Thai L, Chandler JL, Grant I (1994) HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. Am J Psychiatry 151: 237-242
23. Foster R, Olajide D, Everall I (2003) Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med 4: 139-144
24. Bonhoeffer K (1917) Die exogenen Reaktionstypen. Arch Psychiatr Nervenkr 58: 58-70
25. UNAIDS/WHO (2005) AIDS epidemic update: December 2005. WHO Library, Geneva, S Abteilung. Deuticke. Leipzig Wien, S 1-5
26. EuroHIV (2005) HIV/AIDS surveillance in Europe: End-year-report 2004 (No. 71). Euro Surveill 10: E051124.1
27. Robert Koch-Institut (2005a) Zum Welt-AIDS-Tag 2005: Stand und Entwicklung der HIV-Epidemie in Deutschland. Epidemiol Bull 47: 437-446
28. Puchhammer-Stöckl E, Heinz FX (2006) HIV 2005. Institut für Virologie der Medizinischen Universität Wien. Virusepidemiologische Information Nr. 04/06-2
29. Wyszynski AA, Bruno B, Ying P, Chuang L, Friedlander M, Rubenstein B (2005) The HIV-infected patient. In: Wyszynski AA, Wyszynski B (Hrsg) Manual of psychiatric care for the medically ill. American Psychiatric Publishing, Arlington, pp 171-200
30. Albert SM, Weber C, Todak G (1999) An observed performance test of medication management ability in HIV: relation to neuropsychological status and adherence outcomes. AIDS Behav 3: 121-128
31. Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Arfaa K, Ellis RJ, Grant I (1999) The impact of HIV-related neuropsychological dysfunction on driving behaviour. The HNRC Group. J Int Neuropsychol Soc 5: 579-592
32. Sacktor N, McDermott MP, Marder K, Schifitto G, Seines OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein 1 (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8: 136-142
33. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, McCutchan JA, Taylor MJ, Kelly MD, Ellis RJ (1995) The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1: 231-251
34. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP (1993) Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43: 2245-2252
35. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB (1997) Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 11: 1731-1738
36. McArthur (2004) HIV dementia: an evolving disease. J Neuroimmunol 157: 3-10
37. Sewell DD (1996) Schizophrenia and HIV. Schizophr Bull 22: 464-473
38. Lyketsos CG, Hanson AL, Fishman M, Rosenblatt A, McHugh PR, Treisman GJ (1993) Manic syndrome early and late in the course of HIV. Am J Psychiatry 150: 326-327
39. Atkinson JH Jr, Grant I, Kennedy CJ, Richman DD, Spector SA, McCutchan JA (1988) Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry 45: 859-864
40. Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L (1992) Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med 54: 588-601
41. Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B (1997) Prevalence of axis I disorders in an AIDS cohort: a cross-sectional, controlled study. Compr Psychiatry 38: 146-154
42. Lyketsos CG, Hoover DR, Guccione M, Dew MA, Wesch JE, Bing EG, Treisman GJ (1996) Changes in depressive symptoms as AIDS develops. The Multicenter AIDS Cohort Study. Am J Psychiatry 153: 1430-1437
43. Rothenhäusler HB, Kapfhammer HP (2003) Depression bei körperlichen Erkrankungen - Diagnose und Therapie vor konsiliarpsychiattischem Hintergrund. Fortschr Neurol Psychiatr 71: 358-365
44. Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Rosenberger P, Pass RJ (1993) Neuropsychological performance in symptomatic and asymptomatic HIV infection. AIDS 7: 519-524
45. Navia BA, Rostasy K (2005) The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies. Neurotox Res 8: 3-24
46. Power C, Seines OA, Grim JA, McArthur JC (1995) HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr 8: 273-278
47. Price RW, Brew B (1992) The AIDS dementia complex. J Infect Dis 158: 1079-1083
48. Eggers C, Hertogs K, Stürenburg HJ, van Lunzen J, Stellbrink HJ (2003) Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS 17: 1897-1906
49. Eggers C, Rosenkranz T (2005) HIV-Enzephalopathie und HIV-assoziierte Myelopathie. In: Hoffmann C, Rockstroh J, Kamps BS (Hrsg) HIV.NET 2005. Steinhäuser, Wuppertal, S 619-623
50. Wagner-Jauregg J (1928) Malariatherapie. Vortrag, gehalten im Rahmen des Internationalen Fortbildungskurses ü ber Syphilis und Hautkrankheiten am 16. Februar 1928. Wien Med Wochenschr 78: 275-278
51. Harris MJ, Jeste DV, Gleghorn A, Sewell DD (1991) New-onset psychosis in HIV-infected patients. J Clin Psychiatry 52: 369-376
52. Huffman JC, Fricchione GL (2005) Catalonia and psychosis in a patient with AIDS. J Clin Psychopharmacol 25: 508-510
53. Ayuso-Mateos JL (2000) Psychiatric aspects of infections. In: Gelder MG, Lopez-Ibor Jr JJ, Andreasen NC (Hrsg) New Oxford Textbook of Psychiatry. Band 2. Oxford, S 1168-1173
54. Lesho EP, Gey DC (2003) Managing issues related to antiretroviral therapy. Am Fam Physician 68: 675-686
55. Potthoff A, Brockmeyer (2005) Stand der HIV-Infektion 2005. Herz 30: 451-457
56. Lyketsos CG, Schwartz J, Fishman M, Treisman G (1997) AIDS mania. J Neuropsychiatry Clin Neurosci 9: 277-279
57. Kieburtz K, Zettelmaier AE, Ketonen L, Tuite M, Caine ED (1991) Manic syndromes in AIDS. Am J Psychiatry 148: 1068-1070
58. Mijch AM, Judd FK, Lyketsos CG, Ellen S, Cockram A (1999) Secondary mania in patients with HIV infection: are antiretrovirals protective? J Neuropsychiatry Clin Neurosci 11: 475-480
59. McHugh PR (1989) The neuropsychiatry of basal ganglia disorder: A triadic syndrome and its explanation. Neuropsychiatry Neuropsychol Behav Neurol 2: 239-247
60. Treisman G, Fishman M, Schwartz J, Hutton H, Lyketsos C (1998) Mood disorders in HIV infection. Depress Anxiety 7: 178-187
61. Willer A, Saußele S (2005) Individualisierte Therapie der HIV-Infektion. Klinikarzt 34: 319-322
62. McDaniel JS, Purcell DW, Farber EW (1997) Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 17: 311-325
63. Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K (2000) Transdermal selegiline in HIV-associated cognitive impairment: a pilot, placebo-controlled study. Neurology 54: 233-235
64. Zink MC, Uhrlaub J, DeWitt, Voelker T, Bullock B, Mankowski J, Tarwater P, Clements J, Barber S (2005) Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293: 2003-2011
65. Robert Koch-Institut (2005) HIV-Infektionen und AIDS-Erkrankungen in Deutschland. Epidemiol Bull (Sonderausgabe A: 1-16)
66. Wiley CA, Baldwin M, Achim CL (1996) Expression of HIV regulatory and structural mRNA in the central nervous system. AIDS 10: 843-847
67. Lera G, Zirulnik J (1999) Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 14: 128-131
68. Maha A, Goetz K (1998) Risperidone for the treatment of delusional disorder due to HIV. J Neuropsychiatry Clin Neurosci 10: 111
69. Dettling M, Müller-Oerlinghausen B, Britsch P (1998) Clozapine treatment of HIV-associated psychosis - too much bone marrow toxicity? Pharmacopsychiatry 31: 156-157
70. Singh AN, Golledge H, Catalan J (1997) Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 42: 489-493
71. Rothenhäusler HB, Kapfhammer HP (2005) Psychopharmakotherapie bei somalischen Erkrankungen - Behandlungsprinzipien in der medizinischen Routineversorgung. Wien Med Wochenschr 155: 1-12
72. Tanquary J (1993) Lithium-induced neurotoxicity at therapeutic levels in an AIDS patient. J Nerv Ment Dis 181: 518-519
73. Angelino A, Treisman G (2001) Management of psychiatric disorders in patients infected with human immunod-eficiency virus. Clin Infect Dis 33: 847-856
74. Robinson M, Qaqish R (2002) Practical psychopharmacology in HIV-1 and acquired immunodefciency syndrome. Psychiatr Clin North Am 25: 149-175
75. Thome J, Kopf D (2005) Blutbildveränderungen unter Antipsychotika der zweiten Generation. Psychiatr Prax 32: 167-171
76. Singh AN, Catalan J (1994) Risperidone in HIV-related manic psychosis. Lancet 344: 1029-1030
77. Halman MH, Worth JL, Sanders KM, Renshaw PF, Murray GB (1993) Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection. J Neuropsychiatry Clin Neurosci 5: 430-434
78. RachBeisel JA, Weintraub E (1997) Valproic acid treatment of AIDS-related mania. J Clin Psychiatry 58: 406-407
79. Jennings HR, Romanelli F (1999) The use of valproic acid in HIV-positive patients. Ann Pharmacother 33: 1113-1116
80. Cozza KL, Swanton EJ, Humphreys CW (2000) Hepatotoxicity with combination of valproic acid, ritonavir, and nevirapine: A case report. Psychosomatics 41: 452-453
81. Low-Beer S, Chan K, Yip B, Wood E, Montaner JSG, O'Shaughnessy MV, Hogg RS (2000) Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr 23: 295-301
82. Himmelhoch S, Medoff DR (2005) Efficacy of antide-pressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS 19: 813-822
83. Rabkin JG, Rabkin R, Harrison W, Wagner G (1994) Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 151: 516-523
84. Rabkin JG, Wagner GJ, Rabkin R (1999) Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. Am J Psychiatry 156: 101-107
85. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I (1998) Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 59: 217-224
86. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP (1998) Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 155: 367-372
87. Currier MB, Molina G, Kalo M (2004) Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: A prospective study. Psychosomatics 45: 210-216
88. Grassi B, Gambini O, Scarone S (1995) Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry 28: 93-94
89. Elliott AJ, Roy-Byrne PP (2000) Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 20: 265-267
90. Carvalhal AS, de Abreu PB, Spode A, Correa J, Kapczinski F (2003) An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. J Clin Psychiatry 64: 421-424
91. Fernandez F, Levy J (1997) Efficacy of venlafaxine in HIV-depressive disorders. Psychosomatics 38: 173-174
92. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J (2000) A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 161: 411-420
93. Rothenhäusler HB (2005) Pharmako- und psychotherapeutische Ansätze bei depressiven Patienten mit somalischen Krankheiten. Psychotherapie 10: 195-204
94. Rainey PM (2001) HIV drug interactions: the good, the bad, and the other. Ther Drug Monit 24: 26-31
95. Cozza KL, Armstrong SC (2001) Infectious diseases. In: Cozza KL, Armstrong SC (Hrsg) The Cytochrome P450 system. Drug interaction principles for medical practice. Am Psychiatric Press, Washington DC, S 139-162